5Hauner H. The impact of pharmacotherapy on weight management in type2 diabetes[J], Int J Obes Relat Metab Disord, 1999,23(7):12- 17.
6Tremble J M, Donaldson D. Is continued weight gain inevitable in type 2 diabetes mellitus? [J]. J R Soc Health, 1999,119:235- 239,.
7Anonymity. Orlisat a view point by priscilla a hollander [ J], Drugs,2001,61(14) : 2120.
8Heymsfield S B, Segal K R, Hauptman J, et al, Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults[J], Arch Intern Med, 2000,160:1321 - 1326,.
9Davidson M B, Hauptntan J, DiGirolarno M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial[J]. JAMA, 1999,281:235-242,.
10Hollander P A, Elbein S C, Hirsch I B, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study[J]. Diabaes Care, 1998,21 : 1288 - 1294.
3Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch lntem Med,2000,160 : 1321 - 1326.
4Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type2 diabetes treated with mefformin. Diabetes Care,2002,25 : 1123 - 1128.
5Holt R. Orlistat reduces features of the metabolic syndrome : the XEN- DOS study. Diabetes Obes Metab,2003,5 (5) :356.
6Torgerson JS. Randomised study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care,2004,27 ( 1 ) :155 - 161.
